Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 3

Conditions

Ovarian Neoplasms 3Lung Neoplasms 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Pafolacianine × Gynecologic × Clear all
NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

NCT02317705 2022-06-21

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 2 Completed
48 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 3 Completed
140 enrolled 11 charts 1 FDA
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡